Steven Burke
Chief Tech/Sci/R&D Officer bij AKEBIA THERAPEUTICS, INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Steven K.
Burke is currently a Director at LeukoSight, Inc. and AbFero Pharmaceuticals, Inc. He is also the Chief Medical Officer & SVP-Research & Development at Akebia Therapeutics, Inc. He previously worked as the Medical Director & VP-Clinical Research at GelTex Pharmaceuticals, Inc. and as an Associate Director-Clinical Research at Glaxo, Inc. He was also the Chief Medical Officer & Senior Vice President at Proteon Therapeutics, Inc. from 2006 to 2019 and the Chief Medical Officer at Protara Therapeutics, Inc. He holds a doctorate from Weill Cornell Medical College and an undergraduate degree from Harvard College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-02-2024 | 695 840 ( 0.33% ) | 1 M $ | 31-03-2024 |
Actieve functies van Steven Burke
| Bedrijven | Functie | Begin |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17-06-2019 |
LeukoSight, Inc.
 LeukoSight, Inc. Pharmaceuticals: MajorHealth Technology LeukoSight, Inc. develops therapeutics to treat autoimmune and inflammatory diseases. Its categories include apnea, Canadian health and care mall, Canadian pharmacy mall, chronic obstructive airway disease and erectile dysfunction. The company was founded by David M. Mosser in 2007 and is headquartered in College Park, MD. | Director/Board Member | - |
AbFero Pharmaceuticals, Inc.
 AbFero Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Abfero Pharmaceuticals, Inc. engages in the development of pharmaceutical products. It develops oral iron chelators for the treatment of diseases of iron-overload. The company was founded by Steven K. Burke, Raymond J. Bergeron, and Thomas X. Neenan and is headquartered in Boston, MA. | Director/Board Member | - |
Eerdere bekende functies van Steven Burke
| Bedrijven | Functie | Einde |
|---|---|---|
| PROTARA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2019 |
GelTex Pharmaceuticals, Inc.
 GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Chief Tech/Sci/R&D Officer | 01-01-2001 |
| PROTARA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| Glaxo, Inc. | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Steven Burke
| Weill Cornell Medical College | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| PROTARA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Proteon Therapeutics, Inc.
 Proteon Therapeutics, Inc. BiotechnologyHealth Technology Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA. | Health Technology |
| Glaxo, Inc. | |
LeukoSight, Inc.
LeukoSight, Inc. Pharmaceuticals: MajorHealth Technology LeukoSight, Inc. develops therapeutics to treat autoimmune and inflammatory diseases. Its categories include apnea, Canadian health and care mall, Canadian pharmacy mall, chronic obstructive airway disease and erectile dysfunction. The company was founded by David M. Mosser in 2007 and is headquartered in College Park, MD. | Health Technology |
AbFero Pharmaceuticals, Inc.
AbFero Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Abfero Pharmaceuticals, Inc. engages in the development of pharmaceutical products. It develops oral iron chelators for the treatment of diseases of iron-overload. The company was founded by Steven K. Burke, Raymond J. Bergeron, and Thomas X. Neenan and is headquartered in Boston, MA. | Health Technology |
